Urogen Pharma Ltd.

4 trials 1 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

10 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase I (Other)

Phase III: 3 Phase I (Other): 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Bladder cancer 2 Bladder cancer recurrent 1

Top IMPs

MITOMYCIN 2 POLOXAMER 407 1

All trials

4 total

A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting

2024-519343-15-00 Phase III 6 countries MITOMYCIN
A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC. Ended

2023-507261-25-00 Phase III 5 countries POLOXAMER 407
A Phase 3 Single-Arm Study of UGN-102 for Treatment of LG IR NMIBC Ended

2023-506680-34-00 Phase III 7 countries MITOMYCIN
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Ended

2023-508404-37-00 Phase I (Other) 2 countries

Showing 1–4 of 4 trials

← All sponsors A–Z